Charles River Laboratories said its 2026 investor day will center on a refreshed plan aimed at lifting growth and margins through 2030, while also reaffirming its 2026 outlook at the top end of prior ranges.
The company said it expects 2026 revenue growth of 0% to 1%, with results now projected at the upper end of that range. Non-GAAP earnings per share are also expected at the upper end of the prior $11.15 to $11.45 range. Non-GAAP operating margin guidance for 2026 is 21.0% to 21.3%.
Looking further out, Charles River set 2030 targets for organic revenue growth of 5% to 7% annually from 2027 through 2030, compared with the flat-to-1% growth expected in 2026. It is targeting a non-GAAP operating margin of about 24% by 2030, up from the 21.0% to 21.3% range for 2026. The company also expects non-GAAP earnings per share to grow at a low-double-digit compound annual rate from 2027 through 2030.
The company said its “Create the Future” program is expected to generate more than $300 million in cumulative savings from 2027 through 2030 through process simplification, automation, and digital tools.
On the business side, Charles River said it expects bioanalysis revenue to grow at a high-single-digit compound annual rate and reach about $450 million in 2030. It also said its Apollo cloud platform now serves more than 18,000 client users, and has recently been expanded to support manufacturing solutions clients.
Charles River framed the strategy around three priorities: modernizing operations, expanding scientific capabilities, and deepening client engagement. The market has reacted to these announcements by moving the company's shares -2.73% to a price of $277.33. Check out the company's full 8-K submission here.
